Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

18,375 total articles

Mohawk Industries Reports Q1 2026 Results

Mohawk Industries Reports Q1 2026 Results

Mohawk Industries reported Q1 2026 net earnings of $117 million, with adjusted EPS of $1.90 on $2.7 billion in net sales, an 8% increase reported but a 2.6% decline on constant currency and days. The company benefited from productivity improvements and restructuring efforts, offsetting inflationary cost pressures and volume decreases, while the com…

The Ensign Group Reports First Quarter 2026 Results; Raises 2026 Annual Earnings and Revenue Guidance

The Ensign Group Reports First Quarter 2026 Results; Raises 2026 Annual Earnings and Revenue Guidance

The Ensign Group, Inc. announced its first quarter 2026 results showing significant growth in earnings and revenue, with GAAP diluted EPS up 21.9% to $1.67 and adjusted EPS rising 21.7% to $1.85. The firm reported increased occupancy and skilled nursing revenue rates, expanded its healthcare operations portfolio with key acquisitions, and raised it…

Westwood Holdings Group, Inc. Reports First Quarter 2026 Results

Westwood Holdings Group, Inc. Reports First Quarter 2026 Results

Westwood Holdings Group, Inc. reported its Q1 2026 results showing growth in assets under management to $18.3 billion, driven by strong performance in Energy and Real Assets strategies and growth in ETFs and private energy secondaries funds. Quarterly revenues totaled $25.0 million, slightly down from the previous quarter but above last year's firs…

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Cue Biopharma announces the appointment of Shao-Lee Lin, M.D., Ph.D., as CEO, President, and Board Director to steer the company’s transition into a clinical-stage biopharmaceutical company. Dr. Lin brings over 25 years of experience leading biotech firms and advancing drug candidates. The company is progressing its lead autoimmune candidate, CUE-4…

Syntec Optics (Nasdaq: OPTX) Announces Closing of $20 Million Underwritten Public Offering of Common Stock

Syntec Optics (Nasdaq: OPTX) Announces Closing of $20 Million Underwritten Public Offering of Common Stock

Syntec Optics Holdings, Inc. successfully closed a $20 million underwritten public offering of 2,857,142 common shares priced at $7.00 each. The company plans to use the proceeds to acquire or invest in complementary businesses, technologies, products or assets, as well as for working capital, capital expenditures, and to optimize its capital struc…

Provident Financial Services, Inc. Declares Quarterly Cash Dividend

Provident Financial Services, Inc. Declares Quarterly Cash Dividend

Provident Financial Services, Inc. announced a quarterly cash dividend of $0.24 per common share payable on May 29, 2026, to shareholders of record as of May 15, 2026. Provident Financial Services is the holding company for Provident Bank, serving communities in New Jersey, Pennsylvania, and New York with banking, wealth management, and insurance s…

Matrix Service Company Announces CFO Transition

Matrix Service Company Announces CFO Transition

Matrix Service Company, a leading engineering and construction firm for energy and industrial markets, announced that CFO Kevin Cavanah will leave the company after the filing of the fiscal 2026 Annual Report. The company has engaged an executive search firm to find a replacement. The departure is not due to disagreements on accounting or operation…

Trupanion Reports First Quarter 2026 Results

Trupanion Reports First Quarter 2026 Results

Trupanion, Inc., a leading pet medical insurance provider, reported its first quarter 2026 results showing 12% total revenue growth year-over-year to $384 million, driven largely by a 16% increase in subscription revenue. The company achieved net income of $4.9 million, a significant improvement from a net loss in Q1 2025, supported by strong adjus…

Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia

Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia

Larimar Therapeutics announced the publication of research demonstrating that treatment with their lead drug candidate, nomlabofusp, increases frataxin (FXN) levels in tissues relevant to Friedreich’s Ataxia (FA). These frataxin increases correlate between critical tissues and accessible peripheral tissues such as skin and buccal cells, supporting …

Exponent Reports First Quarter 2026 Financial Results

Exponent Reports First Quarter 2026 Financial Results

Exponent, Inc. reported strong first quarter fiscal 2026 results with a 14% increase in total revenues to $166.3 million and a rise in net income to $29.6 million. Growth was fueled by both proactive and reactive engagements, particularly in AI-enabled consumer electronics, utility risk management, and dispute-related services. The company increase…

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions

Century Therapeutics announced an oral presentation of their CNTY-813 iPSC-derived islet cell replacement therapy at the American Diabetes Association's 86th Scientific Sessions. The company highlights progress in developing a scalable, off-the-shelf cell therapy platform engineered to reduce reliance on immunosuppressive drugs for type 1 diabetes …

Jakks Pacific Reports First Quarter 2026 Financial Results

Jakks Pacific Reports First Quarter 2026 Financial Results

JAKKS Pacific reported a 6% decline in net sales to $106.7 million in Q1 2026 compared to the previous year, with a 7% drop in Toys/Consumer Products sales offset partially by a 13% increase in Costumes sales. The company experienced a wider operating loss of $5.6 million and a net loss attributable to common stockholders of $4.3 million, worse tha…

Akebia Therapeutics to Report First Quarter 2026  Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics plans to release its first quarter 2026 financial results on May 7, 2026, prior to market open. The company will hold a conference call at 8:00 a.m. EDT the same day to discuss financials and recent business highlights. Akebia is a biopharmaceutical firm focused on kidney disease treatments, headquartered in Cambridge, Massachus…